Potential New Treatment for COPD Flare-Ups

Trial Objectives

---

People with COPD sometimes have sudden flare-ups that require immediate care in an emergency room, hospital or urgent care facility. For some, these flare-ups are more frequent due to a type of inflammation linked to high levels of eosinophils (a type of white blood cell). Even after treatment, many people experience another flare-up within a month.

The Seabreeze STAT COPD study is testing whether a potentially new medication called rademikibart, when added to standard COPD treatment during a flare-up, can help reduce the risk of symptoms returning or getting worse in the 28 days after urgent care.  If you qualify, you’ll receive either rademikibart or a placebo (a medication containing no active ingredient), along with all usual COPD medications. The study drug or placebo will be given as four injections under the skin during your urgent care visit. Afterward, the research team will follow up with you over the next few months to monitor your health.  You have a 1 in 2 (50%) chance of receiving placebo, but you will continue to receive standard care medications to manage your COPD regardless of which group you're in.